BIOEQUIVALENCE STUDY OF TWO ORAL LINCOMYCIN FORMULATIONS (LINCOCIN® AND BIOLINCO®) IN BROILER CHICKENS
Ashraf Elkomy* and Mohamed Aboubakr
ABSTRACT
The present study was designed to assess the comparative bio-equivalence of Lincocin® and Biolinco® in healthy broiler chicken after oral administration of both products in a dose of 20 mg lincomycin base/kg b.wt. Twenty four broiler chickens were divided into two groups. The first group was designed to study the pharmacokinetics of Lincocin®, while the 2nd group was designed to study the pharmacokinetics of Biolinco®. Each broiler chicken in both groups was orally administered with 20 mg lincomycin base/kg b.wt. Blood samples were obtained from the wing vein and collected immediately before and at 0.08, 0.16, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours after a single oral administration. The disposition kinetics of
Lincocin® and Biolinco® following oral administration of 20 mg lincomycin base /kg b.wt, revealed that the maximum blood concentration of lincomycin [Cmax] were 4.70 and 4.52 μg/ml and attained at [tmax] of 1.37 and 1.39 hours, respectively. In conclusion: Biolinco® is bioequivalent to Lincocin® since the ratios of Cmax, AUC0-24 and AUC0-∞ (T/R) was 0.96, 0.94 and 0.94 respectively. These are within the bioequivalence acceptance range. Biolinco® and Lincocin® are therefore bioequivalent and interchangeable.
Keywords: .
[Download Article]
[Download Certifiate]